🏡 Home≡ MenuNewsA - Z

Stopping Glioblastoma Brain Tumors in their Path

  • Date: 2014/01/09 McGill University - Anita Kar - anita.kar@mcgill.ca - 514-398-3376
  • Synopsis : Study by Montreal Neurological Institute and Hospital sheds new information on Glioblastoma (GBM) the most common and deadly form of brain cancer.

Main Document

New study sheds light on most common and deadly form of brain cancer.

Glioblastoma (GBM) is the most common and deadly form of primary malignant brain cancer accounting for approximately 15% of all brain tumors and occurring mostly in adults between the ages of 45 and 70. The aggressive recurrent nature of this cancer is only temporarily contained by combined surgery, chemotherapy and radiation treatment. The recurrence of GBM is usually fatal, resulting in an average patient survival time of less than two years. A new study from the Montreal Neurological Institute and Hospital - The Neuro - at McGill University, published in Nature Communications , identifies two specific key players in the growth of GBM.

A GBM tumor contains a complex combination of different cell types, including 'stem-like' cells that are able to initiate brain tumor growth, even when present in very small numbers. These cells, known as brain-tumor initiating cells (BTICs), are believed to be among the cells that can re-initiate GBM if they are not completely eradicated through surgery, radiation and chemotherapy. Thus, BTICs represent an important therapeutic target for GBM treatment strategies.

"We wanted to find out how GBM-derived BTICs are able to initiate a tumor with the ultimate goal of preventing the re-growth of this deadly form of brain cancer," says Dr. Stefano Stifani, neuroscientist at The Neuro and senior investigator on the paper. "What we found is that by impairing the activity of two transcription factors (proteins that control gene expression), termed FOXG1 and TLE, we can significantly reduce the ability of BTICs to give rise to brain tumors."

The researchers studied brain tumor growth in an in vivo mouse model using human GBM-derived BTICs. This approach provides what is called an in vivo environment that closely resembles the original human brain tumors. The demonstration that the FOXG1 and TLE proteins are important for the tumor-forming ability of human GBM-derived BTICs has long-term implications because FOXG1 and TLE control the expression of numerous genes. Identifying the genes whose expression is controlled by FOXG1 and TLE is expected to provide further information on the mechanisms involved in GBM tumourigenesis. In the long term, researchers hope to identify multiple important regulators, in order to find new potential therapeutic targets to impair the tumourigenic ability of BTICs.

"The implication of transcription factors FOXG1 and TLE in the tumor-forming ability of BTICs opens the door to possible strategies to block tumor growth - a major advance in the fight against GBM."

The Neuro's Brain Tumor Program sees 3500 patients annually, and performs on average 450 tumor procedures per year. These procedures include surgeries for brain cancers such as GBM and other gliomas, as well as meningiomas, vestibular schwannomas, pituitary adenomas, metastases, among others.

This research, which was supported by the Canadian Institutes of Health Research and the Cancer Research Society, highlights the benefits of The Neuro's integrated model - where clinicians collaborate closely with researchers, to significantly advance neuroscience and clinical care for patients with neurological disease.

• Important Disclaimer: Information provided on disabled-world.com is for general informational and educational purposes only, it is not offered as and does not constitute medical advice. In no way are any of the materials presented meant to be a substitute for professional medical care or attention by a qualified practitioner, nor should they be construed as such. Any third party offering or advertising on disabled-world.com does not constitute an endorsement by Disabled World. All trademarks(TM) and registered(R) trademarks are the property of their respective owners. Please report outdated or inaccurate information to us.